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Trypanosoma cruzi (T. cruzi or Tc) is the causative agent of Chagas disease (CD). It is common for 
patients to suffer from non-specific symptoms or be clinically asymptomatic with acute and chronic 
conditions acquired through various routes of transmission. The expecting women and their fetuses are 
vulnerable to congenital transmission of Tc. Pregnant women face formidable health challenges 
because the frontline antiparasitic drugs, benznidazole and nifurtimox, are contraindicated during 
pregnancy. However, it is worthwhile to highlight that newborns can be cured if they are diagnosed 
and given treatment in a timely manner. In this review, we discuss the pathogenesis of maternal-fetal 
transmission of Tc and provide a justification for the investment in the development of vaccines 
against congenital CD. 
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Highlights 
1. Every year, several Trypanosoma cruzi-infected babies are born to infected mothers in endemic 
and non-endemic countries.  
2. Prompt diagnosis should be mandatory since the treatment of those babies would have a positive 
clinical and epidemiological impact.  
3. Knowledge of the risk factors involved in maternal to fetal transmission would offer novel 
strategies for control of congenital Chagas disease. 
4. Efforts to develop a vaccine that prevents vertical transmission of T. cruzi must be a public health 
priority. 
 
Abbreviations: ASP – amastigote surface protein; BNZ – benznidazole; CD – Chagas disease; CCD – 
congenital Chagas disease; CTB – cytotrophoblast; DTU – discrete typing units; ECG – 
electrocardiogram; ELISA – enzyme-linked immunosorbent assay; GP63 – glycoprotein 63; GPx – 
glutathione peroxidase; HCMV – human cytomegalovirus; IFA – indirect immunofluorescence assay; 
IHA – indirect hemagglutination assay; LAMP – loop-mediated isothermal amplification; LVEF – left 
ventricular ejection fraction; MASPs – mucin-associated surface proteins; MnSOD – manganese 
superoxide dismutase; MVA – modified vaccinia ankara; MHC – major histocompatibility complex; 
NFX – nifurtimox; NLR – nod-like receptor; NO – nitric oxide; PRRs – pattern recognition receptors; 
PARP – poly(ADP-ribose) polymerase 1; PBN – phenyl-alpha-tert-butylnitrone; pPROM – preterm 
pre-labor rupture of the membranes; ROS – reactive oxygen species; RNS – reactive nitrogen species; 
STB – syncytiotrophoblast; SIRT1 – Sirtuin 1; SAPA – shed acute phase antigen; SOCS – suppressor 
of cytokine signaling; TLR – toll-like receptor; T. cruzi or Tc – Trypanosoma cruzi; TESA –
trypomastigote excretory-secretory antigen; TS – trans-sialidase; TSA – trypomastigote surface 




















1.1. Epidemiology of T. cruzi infection and congenital Chagas disease 
 
Trypanosoma cruzi (T. cruzi) is the causative agent of Chagas disease (CD). Transmission of T. 
cruzi occurs by triatomines in the natural environment, though this pathogen is also transmitted 
congenitally, or via blood transfusions, organ donation, lab accidents, and oral ingestion. The 
epidemiological update published by the World Health Organization (WHO) in 2015 [1] and other 
studies [2, 3] show that the prolonged burden of CD in twenty-one Latin American countries affects 6-
7 million people and an additional 71 million people are at risk of infection every year. Due to the 
large-scale migration of Latin Americans over the last few decades, CD has also become an important 
health issue in the USA, Canada, Japan, and Europe [4]. In fact, autochthonous T. cruzi infection via 
vectorial transmission is well documented in the southern parts of the USA [5, 6].  In Europe, most 
migrants from CD endemic areas are concentrated in Spain, Italy, France, the United Kingdom, and 
Switzerland. Serology studies occasionally carried out in Europe, have recorded an overall 4.2% 
prevalence of Tc infection among immigrant Latin Americans, although the highest infection rate of 
18.1% was noted among individuals from Bolivia [7]. However, in most European countries, the 
screening and treatment programs are almost absent [8].  
 
In recent years, congenital Chagas disease (CCD) has emerged as a major health issue in endemic 
and non-endemic countries [7]. Though under-reported and under-estimated, globally >2-million 
women of fertile age are already infected with T. cruzi, and 1-10% of fetuses carried by infected 
mothers are born with CCD [9-11]. In 2010, WHO indicated 8668 new cases of CCD in Latin 
American countries that corresponded to 22% of all new, acute cases of T. cruzi infection that year [1, 
12]. In the USA, a study conducted in 2009 estimated 40,000 women of child-bearing age with chronic 
CD are in the country, and 60-315 cases of CCD were expected to occur annually [13]. However, only 
two cases of CCD were reported [14, 15], likely due to a lack of awareness and an absence of policies 
requiring the training and reporting of CCD among USA pediatricians [16]. In Europe, physicians 
should also be aware of the risk of congenital transmission of T. cruzi to newborns by their infected 
mothers [17]. There is a consensus that the high rate of transmission occurs when women are acutely 
infected and/or exhibit reactivated infection [18]. Prenatal and/or perinatal transmission of T. cruzi to 
the fetus and newborns occurred in 53% of women who became infected during pregnancy [18-21]. 
Women, who were infected with T. cruzi before pregnancy and were exposed to HIV or received 
treatment with immunosuppressive drugs during pregnancy, transmitted Tc to their newborn with a 
much higher frequency [22, 23]. We surmise that the screening of pregnant women and newborns is 
important to restrict transmission and ensure timely treatment. 
 
Historically, CCD has been associated with infected fetuses born with low birth weight, low 
Apgar score, hepatosplenomegaly, respiratory distress syndrome, myocarditis, or meningoencephalitis 
[24]. Recent data collected in Bolivia suggest that 29% of infants born with infection develop clinical 
symptoms of acute cardiac disease [25]. Other infected infants may not exhibit clinically symptomatic 















disorders or chronic cardiomyopathy as they grow to be young adults [10, 26]. The severity of Chagas 
cardiac disease is categorized according to Kuschnir classification [27], depicted in Figure 1: class 0 
displays reactive serology, normal electrocardiogram (ECG), and no cardiac enlargement; class 1 
includes individuals with normal global ventricular function with minor ECG changes, e.g., 
arrhythmias or conduction disorders, and mild echocardiographic contractile abnormalities; class 2 
includes patients exhibiting decreased left ventricular ejection fraction (LVEF) with no other signs of 
heart failure, as well as patients with compromised LVEF in combination with prior or current 
symptoms of heart failure; and class 3 include patients with apical aneurysm and symptoms of heart 
failure at rest that are refractory to maximized medical therapy and require specialized and intensive 
healthcare [28, 29]. 
 
1.2. Current approaches to diagnosis 
 
     Upon T. cruzi infection, acute blood parasitemia can be detected for ~60 days. Direct microscopic 
visualization of circulating trypomastigotes in peripheral blood films or buffy coat smears remains the 
gold standard for diagnosing the acute infection; however, this protocol requires multiple blood draws 
and has relatively low sensitivity [30]. Molecular methods, e.g., traditional and quantitative PCR and 
loop-mediated isothermal amplification (LAMP), can offer a higher level of sensitivity and specificity 
in diagnosing acute T. cruzi infection [31]. Serology studies using trypomastigote excretory-secretory 
antigens (TESA) blot for the detection of IgM-specific shed acute-phase antigen (SAPA) bands were 
 
 
Figure 1. Kuschnir classification for the severity of cardiac disease in Chagas patients. Class 0 and 
class 1 exhibit seropositive antibodies with normal to minor ECG cardiac alterations. Class 2 and class 3 
















able to detect T. cruzi infection in infants at 6 months of age [32, 33]. Other serological tests based on 
anti-Tc IgGs (e.g., indirect hemagglutination assay [34], indirect immunofluorescence assay [35, 36], 
or enzyme-linked immunosorbent assay [34, 37]) are used to identify exposure to T. cruzi in infants of 
9 months or older. A summary of the diagnostic methods that are currently available or are in 
development is presented in Table 1. 
 











Cord or peripheral 
blood of newborn 
collected in capillary 
tubes  microscopic 
observation of the 
parasites in buffy coat. 
Suboptimal sensitivity, 
repeated sampling, 
many variables, e.g., 
operator´s skill, time of 
processing, sample 
quality can affect the 
outcome. 












using cord or peripheral 
blood sample from 
newborn. 
Expensive reagents and 
equipment, need trained 
personnel to avoid 
contamination. 
Best test for early 
detection with high 
sensitivity and 
specificity in the 







Cord or peripheral 
blood culture Tc in 
LIT medium or agar 
blood based medium. 
Trained personnel, risk 
of contamination, time 
consuming, positive 
results take 2-3 months. 








amplification f om 
blood samples. Results 
(+/-) can be visually 
recorded. 
In experimental / 
development stage.  
Potentially easy to apply 










In experimental / 
development stage, cost 
per test not known. 






Immune blotting for 
IgM for TESA antigens 
in serum of newborns. 
Experimental stage, 
requires high operator´s 
skills. 
Less expensive than 
qPCR, and will likely 





-SAPA IgG detection 
in serum by ELISA. 
Available for research, 
not yet used for clinical 
diagnosis. 
Likely allows early 
diagnosis and is less 






of anti-Tc antibodies by 
ELISA, HAI, IFA. 
No major concerns 
Methods of choice for 
diagnosis in most 
clinical labs. Easy to 



















An ideal diagnostic algorithm for identifying congenital transmission of T. cruzi in infants is 
shown in Figure 2. The presented information was adapted from the algorithm developed by the 
  
Figure 2. Diagnostic algorithm proposed for identification of T. cruzi infection in newborns in 
endemic countries. Abbreviations: PCR – polymerase chain reaction, Tc – T. cruzi, ELISA – 
enzyme linked immuno-sorbent assay, IHA – indirect hemagglutination assay, IIF – indirect 
immunofluorescence assay. * Tests for diagnosis of T. cruzi infection in infants can be performed at 
the time of mandatory vaccination, according to country-specific public health policies. 
Newborn from seropositive mother
Tc negative
MicroStrout and/or PCR of peripheral 
blood before hospital discharge
Tc positive Treatment
MicroStrout and/or PCR of peripheral 
blood between 15 – 30 days of life*
MicroStrout and/or PCR of peripheral 
blood between 60 – 90 days of life*
Serology tests x 2 (ELISA, IHA, IIF) 
At 9 months of life *
NOT 
INFECTED
MicroStrout and/or PCR of peripheral 























Hospital system in Salta, Argentina. Though not routinely employed in endemic countries due to a lack 
of resources, it is recommended that maternal seropositive status during pregnancy should be followed 
by testing of the infant for T. cruzi infection during the first year after birth. Until 3 months of age, 
newborn blood samples should be screened for circulating parasites’, detection by microscopic 
micromethod is also known as microStrout, hemoculture, or qPCR [26]. In current practice, infants 
with an inconclusive diagnosis at birth may be screened serologically after 9 months when maternal 
transplacental antibodies have vanished [18]. This algorithm, when used for diagnosis, is very useful 
for treating children, however, only 20% of the infants in Bolivia follow up for nine months for 
unequivocal diagnosis [43]. In our experience, the loss of follow up and treatment of potentially 
infected infants was higher than 80% in an endemic province of Argentina (Campos et al, unpublished 
data). 
 
1.3.  Treatment 
 
  The currently available drugs for the treatment of T. cruzi infection are benznidazole (BNZ) and 
nifurtimox (NFX) (Table 2). Infected children that are 14 years old or younger exhibit a cure rate of  
85% upon treatment with NFX [44, 45]. Unfortunately, NFX causes intense side effects, and therefore, 
children often do not complete the treatment resulting in increased incidences of NFX resistance [46]. 
Clinical studies have shown that BNZ is effective in curing up to 90% of acute or recent cases of 
infection [47-49] with fewer side effects. International guidelines recommend that acute cases (all 
ages) and children up to 14 years old should be treated with anti-parasitic drug therapies [44].  In the 
US, the Food and Drug Administration agency has recently approved BNZ for use in children 2–12 
years of age [50].  
 
The recommended dosage of BNZ and NFX for treatment of young children varies by country 
(Table 2). For example, the CDC recommends BNZ as an oral dose of 5-7.5 mg/kg per day in 2 
divided doses for young children. CCD control programs in Bolivia and Argentina recommend 
treatment with BNZ at 5-10 mg/kg/day for 60 days, in two daily doses, except the first week when it is 
given at 7 mg/kg/day in two doses. Children are monitored to ensure compliance and doses are 
adjusted according to changes in weight and/or tolerance [49, 50]. However, a major issue regarding 
the treatment of infants and children include an absence of accurate diagnosis (discussed above) and a 
lack of drug accessibility. Both BNZ and NFX are contraindicated during pregnancy [51]. Many 
retrospective observational studies have indicated that anti-parasitic treatment of seropositive girls 
before they reach the childbearing age and of seropositive women before their first pregnancy would 
be useful in preventing the congenital transmission. These observational studies have led to strategic 
recommendation(s) that seropositive girls and women in reproductive age should be treated to reduce 






















2. Pathogenesis of congenital transmission 
 
How T. cruzi evades the placental barrier and complex immune responses of the mother, placenta, 
and fetus to establish active congenital infection is not well understood. We discuss our current 
knowledge of the placental, parasitic, maternal, and fetal factors that likely play a role in the risk of 
congenital transmission. 
Table 2: Current drug therapies approved for treatment of T. cruzi infection 
Country 0-2 years 2-12 years 
12 years or 
older 
Remarks References 
     Benznidazole recommended dosages 
Endemic countries 
(e.g., Argentina and 
Bolivia) * 
5-7 mg/kg  
5-7 mg/kg in 
Argentina and 
10 mg/kg in 
Bolivia 
200-300 mg 
Max: 400 mg 
Some countries are 
testing slow release 











countries (e.g., Spain, 
Italy, Switzerland) * 
7-10 mg/kg 10 mg/kg  150 mg 
 
[7, 56] 
     Nifurtimox recommended dosages 
Argentina ** 10-12 mg/kg 
10-12 mg/kg in 
three doses per 
day 
8-10 mg/kg in 




infants are treated with 
lower dose once a day, 
slowly increased to 




Bolivia ** 10-12 mg/kg  12.5-15 mg/kg  
8-10 mg/kg in 
three doses  
[57]  
Spain ** 15-20 mg/kg 12.5-15 mg/kg 
8-10 mg/kg in 
three doses  
[7, 58] 
All dosages are listed per day. 
* Unless stated, treatment is given in two doses per day; and recommended period of benznidazole treatment is 60 days. It 
is acceptable to halt treatment after 30 days in case drug intolerance is noted. If treatment is stopped before 30 days, it is 
recommended to control adverse effects and then start a new cycle of benznidazole treatment.  
** Recommended period of treatment with nifurtimox is 60 days in endemic countries and 90 days in non-endemic 
countries.  This drug is rarely used because of severe side effects.  
***CDC: https://www.cdc.gov/parasites/chagas/health_professionals/tx.html  



















 The placenta is the foremost organ to develop during embryogenesis. It is a maternal-fetal 
organization of tissue for the physiological exchange of gases, nutrients, and wastages. It provides 
hormones, growth factors and immunological protection required for pregnancy. It forms the primary 
barrier between the maternal and fetal compartments protecting the developing fetus from infectious 
agents [59, 60].   
 
Decidua, trophoblastic and chorioamniotic cells establish the maternal-fetal interface of the 
placenta. Fetal trophoblasts differentiate into cytotrophoblasts (CTB), syncytiotrophoblasts (STB) and 
extravillous trophoblasts that form the placental villi and are in direct contact with maternal blood 
present in the intervillous space [59]. Parasites’ invasion of the trophoblast layer is believed to be the 
most common route of transmission to fetal tissues [61] (Figure 3A). Altemani et al [62] performed 
histological analysis comparing placentas from seronegative women without inflammation and 
seropositive placentas  from stillbirths (n=4)  and live births (n=4). In cases of stillbirths, authors noted 
numerous T. cruzi nests and diffused and severe villitis with presence of high number of macrophages 
and granulocytes, low CD4: CD8 ratio, and extensive trophoblastic necrosis. Furthermore, they were 
able to identify parasite infiltration of the trophoblastic barrier and parasitism of the trophoblast and 
stromal cells. In comparison, villitis in live births of s ropositive mothers was focal with only a few 
parasites and no rupture of the trophoblastic barrier. These authors proposed that parasites invade not 
only the trophoblast but also the marginal zone of the hemochorial placenta. Indeed, Fernandez-
Aguilar et al [63] collected placental tissues of infected newborns in Bolivia and showed that parasitic 
lesions were highest at the marginal sinus (Figure 3B), and gradually decreased in the chorionic plate 
and distant membranes. If this is the case, infection can spread and weaken the membranes 
surrounding the fetus, causing pre-term premature rupture of the membranes (pPROM) and preterm 
birth, as reported by Torrico et al [64] (Figure 3C). Host inflammatory reactions to infection in the 
membranes may also cause pPROM and preterm birth [65]. Other groups found parasites in placental 
areas devoid of trophoblast at chorionic plate and amastigotes were seen within membranes of 
amniotic epithelium [19], along with parasitism of the trophoblast and stromal cells at the trophoblastic 
barrier [66, 67]. The trophoblastic epithelium is not present at the marginal zone, and parasites can 
infect and replicate in fibroblasts and macrophages, and potentially transmit through blood vessels 
supplied to the fetus [24, 62].  
 
Vertical transmission could also occur through ingestion of amniotic fluid containing T. cruzi,  
(Figure 3D) [18, 24] or via the hematogenous route from the mother during delivery when there is 

















The currently known anti-parasitic mechanisms of the placenta have been reviewed [68-70]. 
Briefly, studies in human placental explants suggest that chorionic villi denuded of STB were more 
susceptible to T. cruzi infection, thus, indicating that the detachment of the first structure of the 




Figure 3. Potential routes of maternal-fetal transmission of Trypanosoma cruzi (Tc). (A) It is proposed 
that the parasite invades the intervillous space. (B). Alternative transplacental route of vertical transmission 
through marginal sinus is shown. (C) It is also suggested that infection spreads through and weaken the fetal 
membranes that can cause premature rupture and early birth. (D) Congenital transmission may also occur via 

















Moreover, the placenta functions as an active immunological organ. Several innate immune 
receptors, including members of the toll-like receptor (TLR) and nod-like receptor (NLR) families, are 
expressed by extravillous trophoblasts (Figure 5A). These pattern recognition receptors (PRRs) 
recognize the pathogen (or danger) associated molecular patterns (PAMPs and DAMPs, respectively) 
and respond by the activation of the innate immune response at the maternal-fetal interface [71, 72]. It 
was suggested that parasites in the intervillous space trigger the innate immune system, resulting in the 
production of pro-inflammatory cytokines, reactive oxygen species (ROS) and reactive nitrogen 
species (RNS) that can damage the placental barrier [69, 73] and provide an entry for the parasite 
  
 
Figure 4. Diagrammatic presentation of increasing parasitic invasion due to the 















(Figure 5B). Others showed using human placental chorionic villi explants that T. cruzi activated the 
TLR2 innate immune receptor resulting in placental secretion of IL-6 and IL-10 (Figure 5C) which 
can dysregulate trophoblastic turnover [74]. Overall, these studies show that the placenta represents an 
active surface for host-parasite interaction and provides the first barrier to T. cruzi infection. The 
detachment of the placental barrier would increase the chances of congenital transmission [69]. 
 
2.2. Parasitic factors  
 
Currently, T. cruzi is classified into six phylogenic lineages known as DTUs (Discrete Typing 
Units). The DTUs identified in infants born to infected mothers were similar to those present in the 
local population indicating that all DTUs can be transmitted via congenital infection [75-77]. When 
mixed or multiclonal infections were identified in the mother, a predominance of different clones was 




Figure 5. Current understanding of placental immune responses to T. cruzi. (A) Extravillous 
trophoblasts express innate immune receptors, e.g., toll-like receptor 2 (TLR2; purple) and nod-like 
receptor (NLR; green). (B) Reactive oxygen species (ROS; black hexagon) and reactive nitrogen 
species (RNS; red star) are released to kill the parasite, but these reactive species can also damage the 
placental barrier and provide the parasite access to the fetus. (C) Parasite exposure activated the 















transmitted parasite might occur [75, 78, 79]. However, specific parasite factors associated with the 
risk of maternal-fetal transmission are not known.   
 
2.3. Maternal factors 
 
In humans, the congenital transmission of Tc may occur during any trimester of pregnancy. 
However, the transmission of the infectious agent(s) likely occurs after the placental intervillous space 
is opened in 12 weeks of gestation [80] and parasitic transmission probability further increases 
between 22 and 26 weeks of gestation [81]. Additionally, the parasite load of infected women during 
pregnancy is an indispensable factor. It is inferred from preclinical studies that women exhibiting 
parasitemia of 10-20 trypomastigotes/ml of blood will have a higher potential of endangering their 
fetus with Tc infection [11, 19, 24]. Some investigators believe that natural immune tolerance to 
prevent fetal rejection causes an increase in parasitemia in chronically infected women during the 
second and third trimester, and contributes to congenital transmission [82]. Other researchers have 
proposed that the immune system can be activated to control pathogen in pregnant women and thereby 
prevent congenital transmission [83]. This hypothesis is supported by the higher rate of congenital 
transmission in infected women living in non-endemic areas compared to women that are exposed to 
repeated, vector-borne T. cruzi infection, and most likely mount a robust immune response to the 
parasite [84, 85]. Likewise, transmission rates are higher when mothers acquire an acute infection 
during pregnancy or are immunocompromised due to HIV co-infection or other reasons and exhibit 
reactivated acute CD [22, 86]. Further, infected pregnant women who transmitted Tc not only had 
significantly higher parasitic load, but also produced less of IFN- and weak activation of monocytes 
and T cell response [87]. Other studies showed that non-transmitting mothers displayed higher levels 
of TNF- compared to transmitting ones, suggesting that an inflammatory response is elicited to 
control the infection in order to prevent vertical transmission [88]. The role of age of the mother and 
number of pregnancies in increasing the risk of transmission needs further investigation [87, 89]. 
 
2.4. Fetal factors 
 
Generally, neonatal parasitic loads are higher in comparison to maternal parasitemia and easily 
detected up to 3 months after birth. Parasitemia experienced by the infected newborns may also depend 
on the fetal/neonate innate and/or adaptive immune responses [10, 11]. It is described in the literature 
that infected neonates displayed weak innate responses, but stronger T cell responses based on 
cytotoxic T cells, IFN- producing type 1 immune response and increased plasma levels of IL-17 [90, 
91]. These components of fetal immunity may control the parasitic load, but fail to completely protect 
from congenital infection [11]. Others have suggested that the fetal inflammatory response can 
contribute to adverse pregnancy outcomes such as pPROM and spontaneous preterm birth [64, 65]. 
 
 In conclusion, the congenital transmission of T. cruzi is a complex process contingent on a 





















A systematic review of the literature shows that the pathogenesis of Chagas heart disease, 
irrespective of the route of acquisition of infection, is dependent on persistence of low-grade, systemic 
infection with documented adverse immune reactions [92-95]. We have shown that chronic T. cruzi 
infection also causes persistent mitochondrial dysfunction-related oxidative stress in the heart [96-109] 
and it is further exacerbated by inefficient antioxidant capacity [103, 106, 110-114]. Further, we have 
found that ROS directly signal cytokine and chemokine production in infected cardiomyocytes and 
murine hearts [98, 100, 115]. ROS-induced cellular debris and extracellular vesicles produced in CD 
have the capacity to stimulate a pro-inflammatory macrophage response [116]. Thus, the contributions 
of parasite persistence, mitochondrial dysfunction, oxidative stress, and inflammatory infiltrate are not 
mutually exclusive processes in the multi-faceted chronic Chagas disease.  
 
A detailed review of the studies that have provided evidence for protective (vs. pathologic) 
immune responses are published elsewhere [117]. These studies conclude that 1) sub-par innate 
immune responses allow parasite dissemination and delayed kinetics of CD8
+ 
T cells associated with 
mixed type 1/type 2 cytokine responses fail to remove circulating and intracellular parasites and 
contribute to parasite persistence; and 2) an efficient protective response to T. cruzi requires elicitation 
of Th1 cytokines, lytic antibodies, and the concerted activities of phagocytes, T helper cells, and 
cytotoxic T lymphocytes. An important implication of these studies is that arresting infection or the 
acute parasite load below a threshold level would be effective in decreasing the tissue damage and 
clinical severity of CD. These studies provide an impetus for the development of immunotherapies 
against T. cruzi. 
 
 Potential vaccines for the prevention of congenital transmission would target trypomastigote- and 
amastigote-forms of the parasite. Vaccines against infective trypomastigotes that transfer from placenta 
to fetus will prevent the initiation or persistence of infection and limit the parasitemia level/incidence 
in fetal tissues. Vaccines against intracellular replicative amastigotes would arrest the propagation of 
the parasite in the mother as well as in fetal cells and prevent the parasite from re-entering the blood. 
Further, a vaccine should include antigens targeting all lineages of the parasite and be useful as a 
prophylactic as well as a therapeutic vaccine [118].  
 
3.2. Efforts for preventive/therapeutic vaccine development against T. cruzi 
 
The review of historical perspectives on vaccine development against T. cruzi is published 
elsewhere [118-120]. In recent studies, subunit vaccines have been considered as the best choice for 
vaccine development against T. cruzi [121-123]. This is because the T. cruzi genome estimated at > 
100 Mb [124] is highly complex and consists of several large families that account for >18% of the 
total protein-encoding genome in T. cruzi. These families include trans-sialidase (TS) super family 















glycoprotein 63s (GP63s, 174 genes) [124]. Genes included in the large families express shared 
epitopes that can potentially tolerize the T cell response and result in sub-par parasite elimination 
[125]. Others propose that the potential synergistic immunologic advantage of a mixture of epitopes 
from a family with several genes would encourage an elevated frequency of immune effectors in 
heterogeneous host populations and will offer effective immunity against distinct parasite strains [119]. 
Accordingly, members of the TS superfamily, including, trypomastigote surface antigen (TSA-1), TS, 
and amastigote surface proteins (ASP-1, ASP-2, ASP-9) were considered as potential vaccine 
candidates because they have been shown to be recognized by antibody response and CD8
+ 
T 
lymphocytes in infected mice and humans [126-135]. Other antigens, including complement regulatory 
protein [136, 137], lysosomal cysteine proteinase (cruzipain) [138, 139], flagellar calcium-binding 
protein [140, 141], GP90 and GP82 [142-145], kinetoplastid membrane protein 11 [146-148], LYT1 
[149], paraflagellar rod proteins [150-153], Tc52 (glutathione S-transferases) [154] etc. were also 
tested as vaccine candidates in different models of experimental T. cruzi infection. Recently, α-Gal 
glycotype, Galα1,3Galβ1,4GlcNAc (Galα3LN) was used as a candidate vaccine [155]. In conjunction 
with vaccine studies, multiple adjuvants (e.g., IL-12, CD40, HSP70, MALP-2, and CpG 
oligodeoxynucleotides), routes of delivery, concentration and number of doses, and prime-boost 
strategies were tested to skew the vaccine-induced immune responses toward Th1 type and enhance the 
protective long-term efficacy [149, 156, 157]. These candidate prophylactic vaccines provided a 
variable degree of protection, measured based on increased survival and control of blood parasitemia, 
tissue parasite load, and cardiac inflammation (discussed in [158]). 
 
Others have used immunoinformatics to identify potential antigens and epitopes of the major 
histocompatibility complex (MHC) class I. Of the 172 epitopes identified by this approach, 26 were 
tested in mice. Ten of the 26 tested epitopes induced IFN-γ and provided protection from parasitemia, 
cardiac inflammation, and tissue parasite burden [159].  
 
We utilized a computational algorithm to investigate the Tc sequence database for suitable B and 
T epitopes [160, 161]. Next, we implemented a biological screen to locate those that were identified by 
IgGs and/or provoked a type 1 CD8
+
T cell response in infected mice, dogs and humans [160-164]. 
Among the 11 antigens identified, TcG1, TcG2, and TcG4 qualified for vaccine design. These antigens 
a) contained mRNA/protein expression during the mammalian stages of Tc [160, 161], b) are 
discharged in the cell cytoplasm of the host during parasite differentiation [160, 161] and c) consisted 
of epitopes offered by MHC alleles of mice [161], dogs [163, 164], and humans [162]. Remarkably, 
TcG2 and TcG4 were preserved in five of the six Tc lineages (80-96% homology), affording us 
confidence that TcG2/TcG4-vaccine can offer protection against various Tc isolates in the USA and 
Latin America [160].  
 
We followed the protective ability of three antigens TcG1, TcG2, TcG4 in mice and canine 
models. In mice, experiments were conducted with the delivery of the three antigens individually or in 
combination by various prime/boost methods (e.g., DNA/DNA [161], DNA/protein [165], or DNA/ 
Modified Vaccinia Ankara (MVA) [166]). In all cases, prophylactic vaccine provided 80-95% 















Protection was associated with the stimulation of Th1 cytokine response, trypanolytic antibodies, and 
cytolytic activity of CD8
+
 T cells. Notably, these studies indicated an elevated inflammatory response 
in the vaccinated mice closely after challenge infection. Contrarily, chronic inflammatory infiltrates 
were decreased in the vaccinated mice. DNA-DNA prophylactic vaccine was the simplest in design 
[161], while DNA-protein prophylactic vaccine was multifaceted, requiring two doses of six DNA-
encoding plasmids and two doses of three recombinant proteins [165]. MVA has an excellent safety 
record, and MVA itself can act as an adjuvant to signal the innate immune system and boost T cells 









Vaccine-induced immune responses (14 days after delivery of last vaccine dose) 
Antibody levels – + + + + 
Lytic Antibodies – + ++ +++ ++++ 
Cytokines  – ND TH1 low TH1>TH2 TH1>TH2 
CD8
+
 T cells – + + + + 
Immune responses post-challenge infection (10,000 Tc/mouse, 30 dpi) 
Antibody levels + ++ +++ ++++ ++++ 
Lytic Antibodies – + ++ +++ ND 
Cytokines  mixed TH1/TH2 TH1 TH1>TH2 TH1>TH2 
T cell proliferation + ND ++ ++++ ++++ 
CD8
+





 0.5% ND 26% 20% 23% 
CD8
+
 CTLs 1.5% ND 12% 10% 9.5% 
Tc (30 dpi)  ND 90%↓ 91%↓ 89%↓ 90%↓ 
Tc (120 dpi) ND 92%↓ 98%↓ 92%↓ 94%↓ 
Myocarditis 1-3 1-2 0-1 0-2 0-1 
Fibrosis 2-4 0-2 0-1 0-1 0-1 
Prophylactic delivery was used in all studies. 
DNA-DNA: pCDNA3-TcG1, -TcG2, -TcG4 (+ IL-12 and GM-CSF encoding plasmids), 2-4 doses. 
DNA-protein: DNA as above/recombinant TcG1, TcG2, TcG4 proteins, 2-4 doses. 
DNA-MVA: DNA as above/rMVA encoding TcG2 and TcG4, 2 doses. 
DNA: 25-µg each/mouse, intramuscular; Proteins: 25-µg each/mouse, intradermal, MVA: 10
7
pfu/mouse, intradermal. 
Vaccine doses were delivered at 3-week interval. 
  +, ++, +++, and ++++ define the extent of antibody responses, + being lowest level, and ++++ being highest level of anti-
T. cruzi antibodies.  
  Percent increase in splenic CD8
+
T cell frequency (compared to normal controls) was determined by flow cytometry. 
  ND – not determined;  
  Myocarditis/inflammation scoring: (0) - absent/none, (1) - focal or mild with ≤1 foci, (2) - moderate with ≥ 2 
inflammatory foci, (3) - extensive with generalized coalescing of inflammatory foci or disseminated inflammation, and (4) 
- severe with diffused inflammation, interstitial edema, and loss of tissue integrity. 















[167, 168].    
 
Likewise, dogs immunized with TcG1, TcG2, and TcG4- based prophylactic vaccine exhibited 
significant protection from challenge infection and acute myocarditis [163, 164]. Others have shown 
the TcSP- and TcSSP4-encoding DNA vaccine stimulated anti-parasite IgG2 and IFN--producing 
lymphocytic cell proliferation in dogs [169]. Upon challenge infection, dogs immunized with TcSP- 
and TcSSP4-encoding plasmids exhibited a modest control of tissue parasites and electrocardiographic 
irregularities.  
 
Therapeutic vaccines are envisioned to modulate or enhance the multiple effector mechanisms 
against T. cruzi so as to clear the parasite’s persistence in the infected host. Some studies have tested 
TSA-1, TS, and ASP-2 pertaining to the trans-sialidase family as well as Tc52 (glutathione S-
transferases) and Tc24 (a Ca
2+
 binding protein) for therapeutic efficacy in acutely or chronically 
infected mice. When injected immediately after infection or within two weeks post-infection, Tc52-, 
TSA-1-, and Tc24-based DNA therapeutic vaccines decreased the parasitemia and mortality from 





 T cells [172]. However, these same candidates did not control cardiomyopathy in 
chronically infected mice or dogs (reviewed in [173]). ASP2 and TS (individually or in combination as 
a DNA therapeutic vaccine) did not limit parasitemia or improve the survival rate in infected mice 
[171, 174] despite their known efficacy as a prophylactic vaccine [156]. Some studies also observed an 
increase in myocarditis in infected mice inoculated with TSA1 DNA therapeutic vaccine [172].  
 
In our experience, a therapeutic approach focused on controlling only parasites is not sufficient to 
arrest the progression of chronic disease [122]. Treatment with anti-parasitic drug BNZ after immune 
control of acute parasitemia controlled parasite persistence; however, it was not sufficient to avert 
cardiac remodeling and deterioration of ventricular contractility in infected mice and rats [175]. 
Instead, maximal benefits of preserving the structure and function of Chagas heart in rodents were 
obtained when along with parasite control by BNZ; oxidative insult was also controlled by co-delivery 
of PBN (phenyl-alpha-tert-butylnitrone) or vitamin A antioxidants, or by genetic overexpression of 
MnSOD (manganese superoxide dismutase) or GPx (glutathione peroxidase) antioxidants [106, 122, 
176, 177]. Likewise, treatment with sildenafil, an inhibitor of phosphodiesterase 5 provided 
cardioprotection through the preservation of cGMP-PKG activity and antioxidant-oxidant balance in 
chronically infected mice [178]. Sirtuin 1 (SIRT1) maintains mitochondrial metabolic homeostasis and 
prevents the over-activation of inflammation [113]. SIRT1 activity was decreased in CD, and treatment 
with SIRT1 agonist (SRT1720) or inhibition of PARP1 (poly(ADP-ribose) polymerase 1) that 
competes with SIRT1 for substrates reduced oxidative and inflammatory stress in infected cells and 
mice [113, 179]. Moreover, we noted a better efficacy of a therapeutic vaccine in infected GPx 
transgenic mice than in infected/WT mice under similar conditions [122].  
 
Oxidative stress during CCD [73] could potentially be ameliorated with antioxidants delivered in 
conjunction with a therapeutic vaccine. Indeed, several studies have shown the importance of free-















antioxidant vitamin A were associated with the risk of preeclampsia [180]. Schoots et al have 
discussed the adverse consequences of MnSOD deficiency on the integrity of syncytiotrophoblast of 
the placenta [181]. Recently, PBN antioxidant was shown to control the teratogenicity effects of ROS 
in pregnant rats [182] and vitamin C and vitamin E were found to be safe supplements during 
pregnancy [183, 184]. Resveratrol treatment improved the glucose and lipid profile of pregnant mice 
[185]. We, therefore, propose that therapeutic vaccines designed to achieve a rapid, short-term 
stimulation of type 1 cellular immunity to attack the persistent parasites, along with adjunct therapies 
(e.g., PBN or resveratrol) to control the oxidative insult and mitochondrial deficiencies, would prove to 
be maximally beneficial in preserving the tissue homeostasis in congenital and other forms of Chagas 
disease.  
 
3.3. Vaccine and vaccine-induced immunity during pregnancy 
 
As congenital transmission is becoming a global public health issue, strategies towards reducing 
this burden are a priority [7]. Considering anti-parasite drugs are not administered during pregnancy 
because of potential teratogenic effects, we envision three time-points when a vaccine could be useful 
as a public health strategy towards CD elimination. One, a prophylactic vaccine can be used in women 
of childbearing age. Two, a therapeutic vaccine could be given to women who have been chronically 
infected with T. cruzi. Ideally, these women should be vaccinated before conception; however, a 
vaccine designed to enhance maternal immune response, decrease parasitemia, and arrest pathologic 
inflammation and oxidative stress can be given any time during pregnancy. In these women-centric 
approaches, the purpose would be to prevent the exposure to pathogen before or during pregnancy or 
control the parasite burden below a threshold level so that women are protected themselves and they do 
not transmit the parasite to fetus. Three, a therapeutic vaccine can be given to infants born with acute 
T. cruzi infection. Though BNZ is highly effective in treating infection in infants, many times infants 
and children are not followed up because diagnosis of infection and BNZ treatment requires multiple 
visits to the healthcare providers [186]. We believe that anti-parasite immune therapy for children will 
be safe, and it will help to build the protective immunity to control parasitemia and thereby prevent the 
onset of the clinically symptomatic CD in their adult years. 
 
There are potential limitations that need to be overcome in designing a vaccine against CCD. The 
historical concept that pregnancy is associated with immune suppression and increases the 
susceptibility to infection has not been supported by more recent studies [83, 187]. Current studies 
suggest that maternal and placental immune systems cooperate to create a pregnancy-supportive 
immune environment [188]. This relationship prevents a reaction of the mother’s immune response 
against paternal antigens in order to avoid fetal rejection, but simultaneously supports the mother and 
the fetal capability to defend against invading pathogens [187, 188]. However, our understanding of 
the effects of acute or chronic T. cruzi infection on maternal immunity is very limited and remains to 
be further investigated in appropriate experimental models and in pregnant women.  
 
 Current literature indicates that TLRs and type I interferon play a key role in maintaining placental 















differentiate to pro-pregnancy in an IL-10-dependent manner, and produce pregnancy-promoting 
cytokines that regulate spiral artery remodeling and control invasion of trophoblast into the 
endometrium, and thus support placental development (Figure 6A) [189]. The same uNK cells can 
exhibit cytotoxic activity when activated in response to pathogen exposure [190]. Studies evaluating 
the microenvironment of NK cells in the uterus and other tissues (e.g. spleen and muscle tissues for T. 
cruzi) will shed light on how a successful pregnancy is promoted by IL-10-uNK while keeping a 
balance of anti-parasite immunity with vaccination.  
 
Figure 6. Potential maternal immune responses to T. cruzi. (6A) The uterine natural killer (uNK) 
cells differentiate to pro-pregnancy and produce pregnancy-promoting cytokines that regulate and 
support placental development. (6B) In decidua, macrophages of M1 and M2 phenotypes are involved 
in inflammatory responses capable of killing the parasite and tissue renewal and repair critical for 
















 The second most abundant immune cells in human decidua are macrophages (20-25% of total 
leukocytes). In general, M2-like (also referred as alternatively-activated) macrophages involved in 
tissue renewal and repair are critical for normal pregnancy [191]. VEGF (vascular endothelial growth 
factor) plays a significant role in macrophage recruitment and M2 polarization, and inhibition of 
VEGF signaling is suggested to contribute to the shift in macrophage polarity towards M1 (classically-
activated, proinflammatory) phenotype observed in different pregnancy disorders, including 
preeclampsia [192, 193]. Others have indicated that trophoblast secreted factors participate in the 
differentiation of macrophages to a pro-pregnancy phenotype [194]. Zhao and colleagues found that 
IL-10 treatment inhibited apoptosis of human primary trophoblast cells and abnormal pregnancy in 
mice infected with Toxoplasma gondii [195, 196]. In context to T. cruzi infection, pro-inflammatory 
macrophages are necessary for parasite clearance through the induction of ROS and NO (nitric oxide) 
(Figure 6B). Furthermore, macrophages also serve as antigen-presenting cells to stimulate T cell 
immunity, which is required for controlling intracellular parasite replication (reviewed in [102]). Thus, 
our challenge would be to adjuvant the vaccine such that decidual macrophages can be educated to 
differentiate to M1 phenotype for clearance of the pathogen while simultaneously preserving the M2 
phenotype in the placental environment to support fetal development. This phenomenon remains to be 
researched in future studies.   
 
Type I interferons, recognized as potent anti-parasite and anti-viral molecules, also have an 
immunomodulatory function as they activate the suppr ssor of cytokine signaling (SOCS) to regulate 
the overwhelming activation of inflammatory pathways [197]. Placental extracts consist of high 
amounts of type I IFNs, and these molecules are suggested to play an important role as a modulator of 
the maternal immune system [83]. Future studies are needed to understand how type I IFNs affect 
placental function in the presence of infection and/or anti-parasite vaccine.  
 
   
An accumulating body of evidence shows that congenital human cytomegalovirus (HCMV) 
vaccination can influence the incidence of infection and congenital disease (reviewed in [198]). 
Researchers working to develop an HCMV vaccine faced similar concerns as we face today against a 
vaccine for CCD. Yet, both the public and private sectors are heavily engaged in an HCMV vaccine, 
and several vaccine candidates have entered the clinical trials. Thus, we hope that researchers will 
engage and continue to develop unique vaccine designs that will bring an end to the devastating CCD 
in the near future. Our goal would be to design an effective vaccine that can be administered to women 
before or during pregnancy to prevent vertical T. cruzi transmission. The influenza vaccine is shown to 
be harmless and is recommended to be given to pregnant women; comparably we aspire to develop an 
anti-T. cruzi vaccine that would be safe to administer during pregnancy [199].  
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